InvestorsHub Logo
Followers 56
Posts 3222
Boards Moderated 0
Alias Born 09/26/2009

Re: None

Wednesday, 11/18/2020 12:56:36 PM

Wednesday, November 18, 2020 12:56:36 PM

Post# of 5
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders
V.NUMI | 4 hours ago

https://stockhouse.com/news/press-releases/2020/11/18/numinus-announces-compassionate-access-trial-of-psilocybin-assisted

VANCOUVER, BC , Nov. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a company creating an ecosystem of solutions centred on the research, development, and delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies, has announced it will undertake a compassionate access clinical trial of psilocybin-assisted psychotherapy for substance use disorders. This study will enable the company to implement, test, and refine optimal protocols for the use of psilocybin-assisted psychotherapy for participants with a range of substance use disorders and will be conducted in collaboration with Syreon Corporation , a global contract research organization with expertise in conducting clinical trials across a broad range of chronic and complex diseases. The study will involve an initial 30 participants who will take part in a motivational enhancement psychedelic psychotherapy intervention with psilocybin.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.